AT272515B - Process for the production of a wound dressing powder - Google Patents

Process for the production of a wound dressing powder

Info

Publication number
AT272515B
AT272515B AT506867A AT506867A AT272515B AT 272515 B AT272515 B AT 272515B AT 506867 A AT506867 A AT 506867A AT 506867 A AT506867 A AT 506867A AT 272515 B AT272515 B AT 272515B
Authority
AT
Austria
Prior art keywords
sep
hexadecylglycine
santophen
production
wound dressing
Prior art date
Application number
AT506867A
Other languages
German (de)
Original Assignee
Arcana Kommanditgesellschaft D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arcana Kommanditgesellschaft D filed Critical Arcana Kommanditgesellschaft D
Priority to AT506867A priority Critical patent/AT272515B/en
Application granted granted Critical
Publication of AT272515B publication Critical patent/AT272515B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
    • A01N25/04—Dispersions, emulsions, suspoemulsions, suspension concentrates or gels
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N2300/00—Combinations or mixtures of active ingredients covered by classes A01N27/00 - A01N65/48 with other active or formulation relevant ingredients, e.g. specific carrier materials or surfactants, covered by classes A01N25/00 - A01N65/48

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Agronomy & Crop Science (AREA)
  • Dispersion Chemistry (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Description

  

   <Desc/Clms Page number 1> 
 



  Verfahren zur Herstellung eines Wundstreupuders 
 EMI1.1 
 

 <Desc/Clms Page number 2> 

 
 EMI2.1 
 
<tb> 
<tb> 



  {2 <SEP> [ <SEP> (2-Dodecylaminoäthyl) <SEP> amino] <SEP> äthyl} <SEP> glycin,Abtötungskonzentrationen <SEP> gegen <SEP> Staph. <SEP> Aur. <SEP> E. <SEP> coli
<tb> von <SEP> 1. <SEP> Hexadecylglycin
<tb> kein <SEP> Wachstum <SEP> 0, <SEP> 3% <SEP> 2, <SEP> 0%
<tb> Wachstum <SEP> 0, <SEP> 25% <SEP> 1, <SEP> 8%
<tb> 2. <SEP> Tego <SEP> *
<tb> kein <SEP> Wachstum <SEP> 0, <SEP> 015% <SEP> 0, <SEP> 02%
<tb> Wachstum <SEP> 0, <SEP> 012% <SEP> 0, <SEP> 018%
<tb> 3. <SEP> Santophen
<tb> (=o-Benzyl-p-chlorphenol)
<tb> kein <SEP> Wachstum <SEP> 0, <SEP> 18% <SEP> 0, <SEP> 12% <SEP> 
<tb> Wachstum <SEP> 0, <SEP> 16% <SEP> 0, <SEP> 10%
<tb> 4.

   <SEP> Themasept <SEP> II <SEP> 
<tb> kein <SEP> Wachstum <SEP> 0, <SEP> 003% <SEP> 0, <SEP> 03%
<tb> Wachstum <SEP> 0, <SEP> 0025% <SEP> 0, <SEP> 025%
<tb> 
 * N {2[(2-dodecylaminoäthyl)amino]äthyl}glycin 
Hierauf wurden Mischungen hergestellt, welche je die halbe eben nicht biocid wirksame Grenz- konzentration   der Aminosäure und des   Phenols enthielten, sowie Mischungen, welche 10 und 20% weniger als die Hälfte der eben nicht mehr wirksamen Grenzkonzentrationen enthielten. 



  Diese Mischungen wurden wieder auf ihre biocide Wirksamkeit gegenüber dem entsprechenden Bak- terienstamm im Suspensionstest bei 10 min Einwirkungszeit geprüft. 
 EMI2.2 
 
<tb> 
<tb> 



  Mischung <SEP> 1) <SEP> Hexadecylglycin <SEP> + <SEP> Santophen <SEP> Wachstum
<tb> a) <SEP> gegen <SEP> Staph. <SEP> aur. <SEP> : <SEP> 0, <SEP> 125% <SEP> Hexadecylglycin <SEP> + <SEP> 
<tb> 0, <SEP> 08% <SEP> Santophen <SEP> 0
<tb> 0, <SEP> 113% <SEP> Hexadecylglycin <SEP> + <SEP> 
<tb> 0, <SEP> 072% <SEP> Satophen <SEP> 0
<tb> 0, <SEP> 100% <SEP> Hexadecylglycin <SEP> +
<tb> 0, <SEP> 064% <SEP> Santophen <SEP> 0
<tb> b) <SEP> gegen <SEP> Coli <SEP> : <SEP> 0,090% <SEP> Hexadecylglycin <SEP> +
<tb> 0, <SEP> 05% <SEP> Santophen <SEP> 0
<tb> 0, <SEP> 081% <SEP> Hexadecylglycin <SEP> +
<tb> 0, <SEP> 045% <SEP> Santophen <SEP> 0
<tb> 0, <SEP> 072% <SEP> Hexadecylglycin <SEP> +
<tb> 0, <SEP> 04% <SEP> Santophen <SEP> 0
<tb> Mischung <SEP> 2) <SEP> Tego <SEP> + <SEP> Santophen
<tb> a) <SEP> gegen <SEP> Staph. <SEP> aur. <SEP> :

   <SEP> 0, <SEP> 006% <SEP> Tego <SEP> +
<tb> 0, <SEP> 08% <SEP> Santophen <SEP> 0
<tb> 0, <SEP> 0054% <SEP> Tego <SEP> +
<tb> 0, <SEP> 072% <SEP> Santophen <SEP> 0
<tb> 0, <SEP> 0048% <SEP> Tego <SEP> + <SEP> 
<tb> 0, <SEP> 064% <SEP> Santophen <SEP> 0
<tb> b) <SEP> gegen <SEP> Coli <SEP> : <SEP> 0, <SEP> 009% <SEP> Tego <SEP> +
<tb> 0, <SEP> 52% <SEP> Santophen <SEP> 0
<tb> 0, <SEP> 008% <SEP> Tego <SEP> +
<tb> 0, <SEP> 045% <SEP> Santophen <SEP> 0
<tb> 0, <SEP> 007% <SEP> Tego+
<tb> 0, <SEP> 04% <SEP> Santophen <SEP> 0
<tb> 
 

 <Desc/Clms Page number 3> 

 Mischung 3) Hexadecylglycin + Themasept II Wachstum a) gegen Staph. aur.   :

   0, 125z   Hexadecylglycin + 
 EMI3.1 
 
<tb> 
<tb> 0, <SEP> 00125% <SEP> Themasept <SEP> II <SEP> 0
<tb> 0, <SEP> 113% <SEP> Hexadecylglycin <SEP> + <SEP> 
<tb> 0, <SEP> 001120/0 <SEP> Themasept <SEP> 11 <SEP> 0
<tb> 0, <SEP> 100% <SEP> Hexadecylglycin+ <SEP> 
<tb> 0, <SEP> 001% <SEP> Themasept <SEP> II <SEP> 0
<tb> b) <SEP> gegen <SEP> Coli <SEP> : <SEP> 0, <SEP> 090% <SEP> Hexadecylglycin <SEP> +
<tb> 0,0125% <SEP> Themasept <SEP> II <SEP> 0
<tb> 0, <SEP> 081% <SEP> Hexadecylglycin <SEP> +
<tb> 0, <SEP> 011250/0 <SEP> Themasept <SEP> Il <SEP> 0
<tb> 0, <SEP> 072% <SEP> Hexadecylglycin <SEP> +
<tb> 0, <SEP> 01% <SEP> ThemeseptII <SEP> 0
<tb> 
 
 EMI3.2 
 

**WARNUNG** Ende DESC Feld kannt Anfang CLMS uberlappen**.



   <Desc / Clms Page number 1>
 



  Process for the production of a wound dressing powder
 EMI1.1
 

 <Desc / Clms Page number 2>

 
 EMI2.1
 
<tb>
<tb>



  {2 <SEP> [<SEP> (2-dodecylaminoethyl) <SEP> amino] <SEP> ethyl} <SEP> glycine, killing concentrations <SEP> against <SEP> Staph. <SEP> Aur. <SEP> E. <SEP> coli
<tb> from <SEP> 1. <SEP> hexadecylglycine
<tb> no <SEP> growth <SEP> 0, <SEP> 3% <SEP> 2, <SEP> 0%
<tb> growth <SEP> 0, <SEP> 25% <SEP> 1, <SEP> 8%
<tb> 2. <SEP> Tego <SEP> *
<tb> no <SEP> growth <SEP> 0, <SEP> 015% <SEP> 0, <SEP> 02%
<tb> Growth <SEP> 0, <SEP> 012% <SEP> 0, <SEP> 018%
<tb> 3. <SEP> Santophen
<tb> (= o-benzyl-p-chlorophenol)
<tb> no <SEP> growth <SEP> 0, <SEP> 18% <SEP> 0, <SEP> 12% <SEP>
<tb> growth <SEP> 0, <SEP> 16% <SEP> 0, <SEP> 10%
<tb> 4.

   <SEP> Topic sept <SEP> II <SEP>
<tb> no <SEP> growth <SEP> 0, <SEP> 003% <SEP> 0, <SEP> 03%
<tb> Growth <SEP> 0, <SEP> 0025% <SEP> 0, <SEP> 025%
<tb>
 * N {2 [(2-dodecylaminoethyl) amino] ethyl} glycine
Mixtures were then prepared which each contained half the limit concentration of amino acid and phenol which was not biocidally effective, as well as mixtures which contained 10 and 20% less than half of the limit concentration that was no longer effective.



  These mixtures were again tested for their biocidal effectiveness against the corresponding bacterial strain in a suspension test with an exposure time of 10 minutes.
 EMI2.2
 
<tb>
<tb>



  Mixture <SEP> 1) <SEP> Hexadecylglycine <SEP> + <SEP> Santophen <SEP> growth
<tb> a) <SEP> against <SEP> Staph. <SEP> aur. <SEP>: <SEP> 0, <SEP> 125% <SEP> Hexadecylglycine <SEP> + <SEP>
<tb> 0, <SEP> 08% <SEP> Santophen <SEP> 0
<tb> 0, <SEP> 113% <SEP> hexadecylglycine <SEP> + <SEP>
<tb> 0, <SEP> 072% <SEP> Satophen <SEP> 0
<tb> 0, <SEP> 100% <SEP> hexadecylglycine <SEP> +
<tb> 0, <SEP> 064% <SEP> Santophen <SEP> 0
<tb> b) <SEP> against <SEP> Coli <SEP>: <SEP> 0.090% <SEP> hexadecylglycine <SEP> +
<tb> 0, <SEP> 05% <SEP> Santophen <SEP> 0
<tb> 0, <SEP> 081% <SEP> Hexadecylglycine <SEP> +
<tb> 0, <SEP> 045% <SEP> Santophen <SEP> 0
<tb> 0, <SEP> 072% <SEP> Hexadecylglycine <SEP> +
<tb> 0, <SEP> 04% <SEP> Santophen <SEP> 0
<tb> Mixture <SEP> 2) <SEP> Tego <SEP> + <SEP> Santophen
<tb> a) <SEP> against <SEP> Staph. <SEP> aur. <SEP>:

   <SEP> 0, <SEP> 006% <SEP> Tego <SEP> +
<tb> 0, <SEP> 08% <SEP> Santophen <SEP> 0
<tb> 0, <SEP> 0054% <SEP> Tego <SEP> +
<tb> 0, <SEP> 072% <SEP> Santophen <SEP> 0
<tb> 0, <SEP> 0048% <SEP> Tego <SEP> + <SEP>
<tb> 0, <SEP> 064% <SEP> Santophen <SEP> 0
<tb> b) <SEP> against <SEP> Coli <SEP>: <SEP> 0, <SEP> 009% <SEP> Tego <SEP> +
<tb> 0, <SEP> 52% <SEP> Santophen <SEP> 0
<tb> 0, <SEP> 008% <SEP> Tego <SEP> +
<tb> 0, <SEP> 045% <SEP> Santophen <SEP> 0
<tb> 0, <SEP> 007% <SEP> Tego +
<tb> 0, <SEP> 04% <SEP> Santophen <SEP> 0
<tb>
 

 <Desc / Clms Page number 3>

 Mixture 3) Hexadecylglycine + Themasept II growth a) against Staph. aur. :

   0.125z hexadecylglycine +
 EMI3.1
 
<tb>
<tb> 0, <SEP> 00125% <SEP> Topic Sept <SEP> II <SEP> 0
<tb> 0, <SEP> 113% <SEP> hexadecylglycine <SEP> + <SEP>
<tb> 0, <SEP> 001120/0 <SEP> Topic sept <SEP> 11 <SEP> 0
<tb> 0, <SEP> 100% <SEP> hexadecylglycine + <SEP>
<tb> 0, <SEP> 001% <SEP> Topic Sept <SEP> II <SEP> 0
<tb> b) <SEP> against <SEP> Coli <SEP>: <SEP> 0, <SEP> 090% <SEP> hexadecylglycine <SEP> +
<tb> 0.0125% <SEP> Topic Sept <SEP> II <SEP> 0
<tb> 0, <SEP> 081% <SEP> Hexadecylglycine <SEP> +
<tb> 0, <SEP> 011250/0 <SEP> topic sept <SEP> Il <SEP> 0
<tb> 0, <SEP> 072% <SEP> Hexadecylglycine <SEP> +
<tb> 0, <SEP> 01% <SEP> ThemeseptII <SEP> 0
<tb>
 
 EMI3.2
 

** WARNING ** End of DESC field may overlap beginning of CLMS **.

Claims (1)

<Desc/Clms Page number 4> biociden Aminosäurenp- Phenylphenol, o-Benzylphenol, EMI4.1 2, 2' -Methylen-bis (3, 4, 6-trichlorphenol), sowie Pudergrundmasse und Trägersubstanzen (Rest auf 100) miteinander vermischt. EMI4.2 74, 25% Milchzucker, 0, 25% eines Gemisches von 95% 3, 4'-5-Tribromsalicylanilid+ 5% 3,5-Dibromsalicylanilid und 0, So Aerosil vermischt werden. <Desc / Clms Page number 4> biocidal amino acids p- phenylphenol, o-benzylphenol, EMI4.1 2, 2'-methylene-bis (3, 4, 6-trichlorophenol), as well as powder base and carrier substances (remainder to 100) mixed with one another. EMI4.2 74.25% milk sugar, 0.25% of a mixture of 95% 3, 4'-5-tribromosalicylanilide + 5% 3,5-dibromosalicylanilide and 0, So Aerosil are mixed.
AT506867A 1967-05-31 1967-05-31 Process for the production of a wound dressing powder AT272515B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT506867A AT272515B (en) 1967-05-31 1967-05-31 Process for the production of a wound dressing powder

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT506867A AT272515B (en) 1967-05-31 1967-05-31 Process for the production of a wound dressing powder

Publications (1)

Publication Number Publication Date
AT272515B true AT272515B (en) 1969-07-10

Family

ID=3571547

Family Applications (1)

Application Number Title Priority Date Filing Date
AT506867A AT272515B (en) 1967-05-31 1967-05-31 Process for the production of a wound dressing powder

Country Status (1)

Country Link
AT (1) AT272515B (en)

Similar Documents

Publication Publication Date Title
AT272515B (en) Process for the production of a wound dressing powder
CN114027321A (en) Iodine disinfectant and preparation method thereof
EP0362471A1 (en) Prophylactic for fish
DE1618577C3 (en)
DE2221545A1 (en) PROCESS FOR PRODUCING AQUARIUM WATER WITH IMPROVED PROPERTIES
DE743662C (en) Process for improving the water solubility of esters of p- or m-oxybenzoic acid
AT218013B (en) Process for the preparation of the new 1-acetyl-1- (β-hydroxyethyl) -2- (5&#39;-nitrofurfurylidene) hydrazine
FR2224169A1 (en) Antimicrobial fatty acid/amino acid compounds - for use against microorganisms (bacteria, fungi, viruses) in humans, animals and plants
AT90273B (en) Process for the production of long-lasting serum and lymph preparations.
AT120422B (en) Preservatives and disinfectants.
AT100223B (en) Process for the manufacture of bacterial pesticides with increased effectiveness.
AT154710B (en) Means for pest control.
DE689180C (en) Disinfectants
AT108116B (en) Process for the solidification of liquids.
AT151127B (en) Process for the preparation of durable, injectable solutions of laevo ascorbic acid and its analogues.
AT121014B (en) Process for the preparation of compounds containing active oxygen.
DE453808C (en) Disinfectants
DE519488C (en) Seed dressings
AT304930B (en) Fungicidal seed dressing
AT210567B (en) Method for stabilizing an aqueous solution of plant extracts, in particular heart-active plant extracts
AT147629B (en) Method for wrapping dolls with galvanic elements.
DE642753C (en) Preservation of green fodder
AT81069B (en) Process for the preservation of extracts from drugs Processes for the preservation of extracts from drugs. en.
DE127515C (en)
DE881858C (en) Process for the preparation of solutions of sulfathiourea